Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults

Phase 1CompletedNCT00297687

Wyeth is now a wholly owned subsidiary of Pfizer108 enrolled

Overview

To determine the safety \& immunogenicity of a potential vaccine against meningococcal B disease

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

108

Conditions

Meningitis, Meningococcal

Interventions

MnB rLP2086BIOLOGICAL

Eligibility

Sex: ALLMin age: 18 YearsMax age: 25 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy 18-25 year olds Exclusion Criteria: * Prior history of vaccination with any meningococcal vaccine * Prior history of any invasive meningococcal disease

Locations (3)

Unnamed facility

Herson, Queensland, Australia

Unnamed facility

North Adealaide, South Australia, Australia

Unnamed facility

Perth, Western Australia, Australia

Outcomes

Primary Outcomes

Local & systemic safety throughout the trial

Secondary Outcomes

Evidence of an immune response 1 month after dose 2 & 1 month after dose 3

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.